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Donna K. Arnett 5 and Marguerite R. Irvin1
1Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States, 2Department of
Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States, 3Department of Neurology, University of
Alabama at Birmingham, Birmingham, AL, United States, 4Division of Biomedical Informatics and Personalized Medicine,
Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 5College of Public Health,
University of Kentucky, Lexington, KY, United States
Background: African Americans (AAs) suffer a higher stroke burden due to hypertension.
Identifying genetic contributors to stroke among AAs with hypertension is critical to
understanding the genetic basis of the disease, as well as detecting at-risk individuals.
Methods: In a population comprising over 10,700 AAs treated for hypertension from the
Genetics of Hypertension Associated Treatments (GenHAT) and Reasons for Geographic
and Racial Differences in Stroke (REGARDS) studies, we performed an inverse variance-
weighted meta-analysis of incident stroke. Additionally, we tested the predictive accuracy
of a polygenic risk score (PRS) derived from a European ancestral population in both
GenHAT and REGARDS AAs aiming to evaluate cross-ethnic performance.
Results: We identified 10 statistically significant (p < 5.00E-08) and 90 additional
suggestive (p < 1.00E-06) variants associated with incident stroke in the meta-
analysis. Six of the top 10 variants were located in an intergenic region on
chromosome 18 (LINC01443-LOC644669). Additional variants of interest were located
in or near the COL12A1, SNTG1, PCDH7, TMTC1, and NTM genes. Replication was
conducted in the Warfarin Pharmacogenomics Cohort (WPC), and while none of the
variants were directly validated, seven intronic variants of NTM proximal to our target
variants, had a p-value <5.00E-04 in the WPC. The inclusion of the PRS did not improve
the prediction accuracy compared to a reference model adjusting for age, sex, and genetic
ancestry in either study and had lower predictive accuracy compared to models
accounting for established stroke risk factors. These results demonstrate the necessity
for PRS derivation in AAs, particularly for diseases that affect AAs disproportionately.
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Conclusion: This study highlights biologically plausible genetic determinants for incident
stroke in hypertensive AAs. Ultimately, a better understanding of genetic risk factors for
stroke in AAs may give new insight into stroke burden and potential clinical tools for those
among the highest at risk.
Keywords: incident stroke, hypertension, antihypertensives, disparities, polygenic risk score, genome wide
association studies
INTRODUCTION
As the second-leading global cause of death and a leading cause of
disability-adjusted life-years lost (Katan and Luft, 2018), stroke is
a major public health burden especially among African
Americans (AAs) who have a 50% higher risk of stroke
(Howard et al., 2011). The role of genetics on stroke risk has
been evidenced through twin studies, where monozygotic twins
are more likely to be concordant than dizygotic twins (odds ratio
for concordance (OR): 1.65, 95% CI: 1.2–2.3) (Flossmann et al.,
2004). Previously reported heritability estimates of stroke based
on data from genome-wide association studies (GWAS) are
comparable for AAs and individuals of European Ancestry
(EAs); 38% for EAs (Bevan et al., 2012) and 35% for AAs
(Traylor et al., 2017), yet AAs contribute far less data to a
large body of literature on stroke genetic risk factors (Bentley
et al., 2020).
GWAS of stroke in European populations have identified
susceptibility loci located on chromosomes 4q25 and 9p21
(Gretarsdottir et al., 2008), 7p21.1 (International Stroke
Genetics, 2012), 6p21 (Holliday et al., 2012), 12p13 (Ikram
et al., 2009), 12q24 (Kilarski et al., 2014), and 16q22 (Traylor
et al., 2012). Overall, there has been a lack of similar primary
GWAS discovery efforts in AAs, and results from EAs have not
generally replicated in AAs (Carty et al., 2015; Peprah et al., 2015).
For example, of 520,000 participants in the large trans-ethnic
GWASmeta-analysis from the MEGASTROKE consortium, only
∼4% of participants were AAs (Malik et al., 2018). The only other
study with a large number of AAs, the Consortium of Minority
Population Genome-Wide Association Studies of Stroke
(COMPASS), confirmed the need for race-specific stroke
discovery, finding weak or no validation across ethnic groups
(Carty et al., 2015; Keene et al., 2020). Given the relative lack of
data on this race group in the published literature, additional
stroke variant discovery in this population remains needed.
GWAS data capitalizes on the polygenic nature of common
diseases and has been collected on a large scale to provide useful
health information over traditional clinical risk factors. So far
GWAS data at the single variant level, even from large consortia
studies such as those described above, has been difficult to
translate to the clinic. More recently, cumulative single variant
effects from GWAS, at thousands to millions of variants, are
being used to estimate polygenic risk scores (PRS), which may
prove useful for stroke risk prediction and prevention.
Unfortunately, few stroke PRS have been developed in
populations including AAs and, to the best of our knowledge,
only one PRS was developed exclusively in individuals of African
descent, consisting of only 29 variants (Traylor et al., 2017).
Abraham et al. (2019) comprised a composite meta-risk PRS
(metaPRS) for ischemic stroke leveraging publicly available
GWAS data for stroke and 19 stroke-related phenotypes
generated from the British European dataset of the
United Kingdom Biobank (UKB, n  407,388). Under a split
sample design, participants with ‘any stroke’ event were
oversampled for the derivation set (n  11,995 total; n  2,065
with “any stroke” events) followed by validation in the remaining
∼395,000 participants. The authors did not report on score
validation in the small sample of available individuals of
African descent from the UKB (N∼8,000). Given difficulties in
cross-ethnic validation of stroke variants in GWAS, we suspected
that the publicly available Abraham composite metaPRS will not
perform adequately in AAs.
The goals of the current study, which we set among AAs at
elevated risk for stroke due to hypertension (HTN), were two-
pronged. First, we aimed to increase stroke GWAS data available
in this race group using data from the Genetics of Hypertension
Associated Treatments (GenHAT) study and the Reasons for
Geographic and Racial Differences in Stroke (REGARDS) studies.
Second, we aimed to assess the predictive ability of the UKB
derived stroke PRS (Abraham et al., 2019) in these two
populations given the lack of previous cross-ethnic validation.
MATERIALS AND METHODS
Study Participants
GenHAT was an ancillary pharmacogenetic study to the
Antihypertensive and Lipid-Lowering Treatment To Prevent
Heart Attack Trial (ALLHAT) and REGARDS is an ongoing
cohort study of stroke risk in the continental US. The GenHAT
and REGARDS studies contributed genetic and phenotypic data
on 10,717 AAs with HTN at baseline (GenHAT n  6,908;
REGARDS n  3,809), further detailed in the Supplementary
Material. Participants in GenHAT were randomized to either
chlorthalidone, a thiazide diuretic (TD), or lisinopril, an
angiotensin-converting enzyme (ACE) inhibitor, while
REGARDS participants were taking a TD, ACE inhibitor, or a
combination of both for inclusion in the analysis
(Supplementary Table S1). All studies were approved by local
institutional review boards and/or ethics committees. All
participants provided written informed consent.
Definition of Incident Stroke
In GenHAT, incident stroke was defined as the rapid onset of
persistent neurologic deficit attributable to an obstruction or
rupture of the arterial system, including stroke occurring
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during surgery, not known to be secondary to brain trauma,
tumor, infection, or other non-ischemic cause and must last more
than 24 h unless death supervenes or there is a demonstrable
lesion compatible with acute stroke on CT or MRI scan
(ALLHAT Protocol, 2000). In REGARDS, any suspected
stroke events were identified every 6 months via telephone
interview. The medical records associated with these events
were retrieved and adjudicated by a physician, using the
World Health Organization definition of stroke as focal
neurologic symptoms lasting more than 24 h or those with
neuroimaging data consistent with stroke (WHO Task Force
on Stroke and other Cerebrovascular Disorders, 1989; Howard
et al., 2011). For REGARDS, all stroke events occurring before or
on September 30, 2019 were included in this analysis. REGARDS
participants with a history of previous stroke were excluded.
Genotyping, Quality Control, and Imputation
Genome-wide genotyping was performed within each study
independently using Illumina Infinium Multi-Ethnic AMR/
AFR Extended BeadChip arrays (MEGA chip; Illumina, Inc.,
San Diego, CA). Supplementary Table S2 includes detailed
information on the variant and sample quality control (QC).
Filtered genotype calls were imputed using the NHLBI Trans-
omics for Precision Medicine (TOPMed) release 2 (Freeze 8)
reference panel, which leverages data on ∼186,000 samples (∼30%
AA) (Fuchsberger et al., 2015; Das et al., 2016; Taliun et al., 2021).
Post-imputation QC excluded variants with imputation quality
scores (Rsq) < 0.3 and a Minor Allele Count (MAC) < 20 in each
cohort, as previously described using TOPMed data (Sarnowski
et al., 2021). The variants not represented in both GenHAT and
REGARDS were excluded from subsequent analyses.
Statistical Analysis
Baseline descriptive statistics for cases and controls are presented
as counts (percentages) for categorical variables or mean
± standard deviation (SD) for continuous variables, and were
compared using χ2 tests and t-tests, respectively (Table 1).
Firth logistic regression models implemented in PLINK2 (Ma
et al., 2013; Chang et al., 2015) were used for genome-wide
association analysis of incident stroke status. Models of the
imputed effect allele dosage were adjusted for age, sex, and the
top 10 principal components (PCs) for ancestry derived in
EIGENSTRATv6.1.4 (Price et al., 2006). An inverse variance-
weighted, fixed effects meta-analysis was performed on the
summary statistics from GenHAT and REGARDS, using
METAL software (Willer et al., 2010). Statistical
heterogeneity was evaluated using Cochran’s chi-square test
in METAL. Regional plots were created using LocusZoom
v0.12 (Pruim et al., 2010; Boughton et al., 2021). Gene
annotation was completed using ANNOVAR (Wang et al.,
2010). Genome-wide significance was set at p < 5.00E-08 after
a Bonferroni correction for multiple testing. A randomization
drug-adjusted sensitivity model was performed in the
GenHAT data to account for any effects of the
antihypertensive agent, and the results were similar to the
discovery model (data not shown). To address potential issues
associated with case-control imbalance, we ran sensitivity
analyses in the GenHAT and REGARDS data using the
saddle point approximation (SPA) in the Scalable and
Accurate Implementation of Generalized (SAIGE) program
and meta-analyzed the results (Zhou et al., 2018). This
approach provides good control of type 1 error for binary
traits, however the SPA approach in SAIGE is very
conservative and has been described to result in inflated
effect-size estimates (Mbatchou et al., 2021). To determine
if there are any shared genetic risk factors for stroke with EAs,
we conducted a fixed effects, inverse-variance weighted meta-
analysis incorporating top (p < 1.00E-07) variants (n  356)
from the publicly available MEGASTROKE European analysis
summary statistics (Malik et al., 2018).











Age, years 68.70 ± 8.19 66.02 ± 7.70 <0.001 67.41 ± 9.01 64.42 ± 8.81 <0.001
Sex
Male 191 (52.2%) 2,893 (44.2%) 0.003 102 (36.4%) 1,310 (37.1%) 0.868
Female 175 (47.8%) 3,649 (55.8%) 178 (63.6%) 2,219 (62.9%)
Antihypertensive class
Thiazide diuretic 190 (51.9%) 4,107 (62.8%) <0.001 88 (31.4%) 1,418 (40.2%) 0.013
ACE Inhibitor 176 (48.1%) 2,435 (37.2%) 123 (43.9%) 1,311 (37.1%)
Combination therapya NA NA 69 (24.6%) 800 (22.7%)
Cigarette smoking 89 (31.7%) 1,506 (27.1%) 0.104 39 (14.0%) 591 (16.8%) 0.255
DM 188 (51.4%) 2,588 (39.6%) <0.001 136 (49.5%) 1,325 (38.2%) <0.001
BMI 29.65 ± 6.34 30.52 ± 6.60 0.014 31.20 ± 5.81 31.83 ± 6.76 0.126
SBP, mmHg 148.37 ± 15.98 146.13 ± 15.75 0.008 135.65 ± 16.90 132.03 ± 16.78 0.001
DBP, mmHg 84.64 ± 10.90 84.88 ± 10.12 0.667 78.42 ± 10.41 78.74 ± 10.04 0.603
eGFR, mL/min/1.73 m2 78.62 ± 22.88 82.95 ± 21.68 <0.001 83.44 ± 25.52 86.47 ± 27.59 0.079
aGenHAT participants were taking either thiazide diuretic or ACE inhibitor at baseline.
Categorical variables are described as N (%), while continuous variables are described as mean ± standard deviation. Abbreviations: TD, thiazide diuretic class; ACE, angiotensin-
converting enzyme; DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate.
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To analyze the putative biological mechanisms of a subset of
significant and suggestive variants identified in the meta-analysis
with p < 1.00E-06, we utilized the Functional Mapping and
Annotation of Genome-Wide Association Studies (FUMA)
version 1.3.6a online platform and the GENE2FUNC process
(Watanabe et al., 2017). Within FUMA, over 22,000 genes
underwent zero-mean normalization and log2 transformation
of the expression values [zero mean of log2 (reads per kilobase per
million +1)]. Differentially expressed gene (DEG) sets for each of
the 53 specific tissue types from the Genotype-Tissue Expression
(GTEx) project version eight RNA sequencing data (GTEx
Consortium, 2017), were determined from two-sided Student’s
t-test performed per gene per tissue type against all other tissue
types. Genes with p ≤ 0.05 after Bonferroni correction and
absolute log fold change of ≥0.58, were included in the DEG
set for a given tissue (Watanabe et al., 2017). Furthermore, FUMA
distinguished between genes that were upregulated and
downregulated in a specific tissue type compared to other
tissues via the sign of the t-statistic (Watanabe et al., 2017).
Genes identified from the meta-analysis were uploaded into
FUMA and mapped to Ensembl identifiers. Our prioritized
genes were tested against biologically relevant tissue (brain n 
12, artery n  3, heart n  2, and kidney n  2) DEG sets using
hypergeometric tests to evaluate if the targeted genes were
overrepresented in FUMA DEG sets in specific tissue types.
Multiple testing correction was performed using a Benjamini-
Hochberg adjustment. Statistical significance was calculated
using a p-threshold of p < 0.05.
We utilized the publicly available risk score weights for the
Abraham metaPRS to assess the predictive accuracy of this score
in both GenHAT and REGARDS AAs (Abraham et al., 2019).
Specifically, the PRS were generated separately for each study
population using the allelic scoring option in PLINK2, resulting
in the inclusion of 466,657 and 466,614 variants in GenHAT and
REGARDS, respectively. We then employed a series of nine
logistic regression models. Model 1 (reference model)
regressed the ‘any stroke’ outcome on age, sex, and PCs 1–10.
The metaPRS and clinical risk factors (SBP, DBP, DM, baseline
cigarette smoking, or BMI) were individually added toModel 1. A
clinical model added each clinical risk factor (SBP + DBP + DM+
baseline cigarette smoking + BMI) to model 1. Lastly, we
generated a composite model that consisted of Model one plus
clinical factors and the metaPRS (SBP + DBP + DM + baseline
cigarette smoking + BMI + metaPRS). Using the predicted values
for stroke, the performance of each model was determined by the
area under the receiver operator characteristic (ROC) curve
(AUC). Delong’s test for two correlated ROC curves compared
the pairwise performance of the nested models (i.e., model one to
each of the subsequent models). The fit of each model was
determined by Nagelkerke’s pseudo-R2. All predictive
regression modeling and model fit calculations were performed
in R version 3.6.2.
Replication for Meta-analysis
We sought replication in AAs from the University of Alabama at
Birmingham Warfarin Pharmacogenomics Cohort (WPC)
(Shendre et al., 2016; Yanik et al., 2017). The WPC replication
population included 790 AAs, of which 145 had an incident
stroke. In the WPC, incident stroke case-control status was
regressed onto genotypes imputed to the TOPMed release 2
(Freeze 8) reference panel, adjusting for age, sex, the top 4
PCs, and genotyping platform using PLINK2. Further details
are described in the Supplementary Material. We also expanded
our replication lookups to the region around our index variants
from the meta-analysis. Based on prior research, we considered a
window within 100 KB of the target variant (Genomes Project
et al., 2015).
Further replication was obtained using the publicly available
summary statistics from the recent COMPASS meta-analysis
study (Keene et al., 2020). In the COMPASS meta-analysis,
22,051 AAs were included, of which 3,734 had a physician-
adjudicated stroke. Due to the imputation reference panel
differences (TOPMed vs. 1,000 Genomes), we did not have
sufficient overlap to replicate on the variant level. Our
replication efforts examined all variants located in the gene
region [5′ untranslated region (UTR) through the 3′ UTR] of
the target variant, or in the case of intergenic variants, the entire
region between the two flanking genes. Of note, there is an
overlap of 864 participants (66 cases) from our discovery
REGARDS population and those included in the published
COMPASS meta-analysis of IS, which could inflate the results
on a single-variant level.
RESULTS
The baseline characteristics for GenHAT and REGARDS
participants are presented in Table 1. In the 6,908 GenHAT
participants, approximately 5% (n  366) had an incident stroke.
Males comprised approximately 52% of stroke cases and 44% of
controls. The average age of cases was nearly 69 years of age, while
the controls were younger at 66 years (p < 0.001). In GenHAT,
stroke cases were more likely current cigarette smokers (32% v.
27%; p  0.104) and diabetic (51% v. 40%; p < 0.001) compared to
controls. Likewise, stroke cases had worse kidney function as
estimated by the mean glomerular filtration rate (eGFR) (78.62 v.
82.95 ml/min/1.73 m2; p < 0.001), higher mean SBP (148.37 v.
146.13 mmHg; p  0.008) and a negligible difference in mean
DBP (84.64 v. 84.88 mmHg; p  0.667) compared to controls.
In the 3,809 REGARDS participants, approximately 7% (n 
280) had an incident stroke. Males comprised approximately 36%
of incident stroke cases versus 37% of controls. The average age of
stroke cases was 67 vs. 64 years for controls (p < 0.001). Of stroke
cases, 14% were current cigarette smokers compared to 17% of
controls (p  0.255), and almost 50% had DM versus 38% of
controls (p < 0.001). The stroke cases had slightly higher baseline
SBP (135.65 mmHg v. 132.03 mmHg; p  0.001), lower baseline
DBP (78.42 mmHg v. 78.74 mmHg; p  0.603), and worse kidney
function (83.44 ml/min/1.73 m2 v. 86.47 ml/min/1.73 m2; p 
0.079) compared to controls (Table 1).
In Table 2, we present 21 top variants (p < 1.00E-07) across
nine unique genes, of which 10 variants were statistically
significant (p < 5.00E-08) from the inverse variance-weighted
meta-analysis (Figure 1). An additional 79 variants were
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marginally significant (p < 1.00E-06) and are described in
Supplementary Table S3. In the sensitivity analysis using
SAIGE, we observed consistent results in our top finding,
although we saw marginal reduction in the significance
(Supplementary Table S4). The most significant variant,
rs117880209 (p  6.45E-09), was located in the intergenic
region between LINC01443 and LOC644669 on chromosome
18. At this variant the odds ratio for incident stroke was 2.98
(95% CI 2.06-4.31) for the C (v. T) allele and the direction of the
effect was consistent across both GenHAT and REGARDS. An
additional 10 variants in this intergenic region met or exceeded
p < 1.00E-06.
Furthermore, we observed 13 intronic variants in COL12A1 on
chromosome 6 with p < 1.00E-6. One intronic variant in this
gene, rs144162260, reached statistical significance (p  1.25E-08;
OR  4.32; 95% CI  2.61–7.15). Three additional variants
exceeded genome-wide significance, including two intergenic
variants between TMTC1 and IP O 8 (top variant:
rs536017124; p  1.32E-08; OR  4.79; 95% CI  2.79–8.22),
and one intronic variant of PTPRR (rs568505299; p  2.64E-08,
OR  3.95, 95% CI  2.44–6.41) (Table 2).
Other variants of biological interest include 11 intergenic
variants between LINC02472 and PCDH7 (top variant:
rs74599173, p  8.09E-08), three intronic variants of SNTG1
(top variant: rs117962542, p  5.91E-08), and two intronic
variants of NTM (top variant: rs185159493, p  1.37E-07)
(Table 2; Supplementary Table S3). The genomic inflation
factor (λ) from the individual cohorts (GenHAT λ  0.952;
TABLE 2 | Top variants (p < 1.00E-07) associated with incident stroke from inverse variance-weighted meta-analysis.
rsID CHR BP (hg38) A1/A2 EAF OR 95% CI ap bDirection Location Gene(s)
rs117880209 18 14,996,132 C/T 0.012 2.98 2.06, 4.31 6.45E-09 −− intergenic LINC01443; LOC644669
rs144162260 6 75,188,146 G/T 0.005 4.32 2.61, 7.15 1.25E-08 −− intronic COL12A1
rs117791256 18 15,006,517 C/G 0.011 2.95 2.03, 4.28 1.31E-08 ++ intergenic LINC01443; LOC644669
rs536017124 12 30,539,571 A/C 0.004 4.79 2.79, 8.22 1.32E-08 ++ intergenic TMTC1; IPO8
rs142422295 18 15,015,740 C/T 0.011 2.93 2.02, 4.25 1.51E-08 −− intergenic LINC01443; LOC644669
rs145341988 18 15,015,569 T/C 0.011 2.93 2.02, 4.25 1.51E-08 ++ intergenic LINC01443; LOC644669
rs140550089 18 15,003,860 C/T 0.011 2.93 2.02, 4.25 1.51E-08 −− intergenic LINC01443; LOC644669
rs192840029 12 30,513,818 A/G 0.004 4.67 2.72, 8.00 2.17E-08 ++ intergenic TMTC1; IPO8
rs568505299 12 70,890,293 T/C 0.005 3.95 2.44, 6.41 2.64E-08 ++ intronic PTPRR
rs58633304 18 14,988,000 C/A 0.013 2.76 1.93, 3.96 2.79E-08 −− intergenic LINC01443; LOC644669
rs186234470 15 48,470,292 T/C 0.011 2.77 1.92, 4.00 5.20E-08 ++ intronic FBN1
rs117962542 8 50,357,386 A/G 0.003 5.59 3.00, 10.41 5.91E-08 ++ intronic SNTG1
rs116671900 5 1,833,726 T/C 0.002 7.60 3.64, 15.87 6.59E-08 ++ intergenic NDUFS6; LINC02116
rs145817478 6 75,173,029 G/A 0.004 4.27 2.52, 7.23 6.70E-08 −− intronic COL12A1
rs74599173 4 30,537,733 A/G 0.004 4.48 2.59, 7.74 8.09E-08 ++ intergenic LINC02472; PCDH7
rs77853510 4 30,553,234 A/G 0.004 4.48 2.59, 7.74 8.09E-08 ++ intergenic LINC02472; PCDH7
rs118141576 8 50,326,925 A/T 0.003 5.09 2.81, 9.22 8.18E-08 ++ intronic SNTG1
rs541454296 12 70,806,203 C/T 0.003 5.52 2.95, 10.31 8.72E-08 −− intronic PTPRR
rs143089250 6 28,694,541 C/T 0.003 5.79 3.04, 11.04 9.02E-08 −− intergenic LINC00533; LINC01623
rs117306,905 18 15,004,526 T/C 0.013 2.67 1.86, 3.84 9.50E-08 ++ intergenic LINC01443; LOC644669
rs75989184 4 30,534,014 G/C 0.004 4.42 2.56, 7.63 9.93E-08 −− intergenic LINC02472; PCDH7
aGenome-wide statistical significance after multiple testing correction, p < 5.00e-08.
bDirection order: GenHAT, REGARDS.
Abbreviations: rsID, reference SNP cluster ID; CHR, chromosome number; BP, base position from hg38; A1, effect allele; A2, allele 2; EAF, effect allele frequency; OR, odds ratio; CI,
confidence interval.
FIGURE 1 |Manhattan plot depicting the top associations with incident stroke in GenHAT-REGARDS meta-analysis. The dotted line is representative of genome-
wide significance (p < 5.00E-08).
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REGARDS λ  1.002) and the meta-analysis (λ  0.992) showed
no evidence of systematic inflation (Supplementary Table S5;
Supplementary Figure S1). LocusZoom plots of the top variants
in COL12A1, PTPRR, NTM, and the intergenic regions of
LINC01443- LOC644669, TMTC1- IP O 8, and LINC02472-
PCDH7, show that the suggestive variants within these regions
are in moderate-to-strong linkage disequilibrium (LD) with the
sentinel variant (Supplementary Figures S2–S7). Variant-
specific LD estimates generated from the GenHAT/REGARDS
data are shown in Supplementary Table S6.
None of our single variant results were replicated in
individuals from the WPC at a threshold of p < 5.00E-04 (p 
0.05/100 suggestive variants from Table 2 and Supplementary
Table S3). Of the 10 statistically significant variants, rs144162260
in COL12A1, rs536017124 and rs192840029 in the TMTC1-IPO8
intergenic region, and rs58633304 in the LINC01443-LOC644669
intergenic region had the same direction of effect but non-
significant p-values (Supplementary Table S3). Our extended
look-up of variants ±100 kb of the target variant, identified seven
intronic variants within the NTM gene that had p-values <5E-04.
These variants were all located within 60 kb from either
rs185159493 or rs184866696 (Supplementary Table S7).
Our lookup efforts in the COMPASS summary statistics
provided marginal support for replication at the gene level, as
none of the variants from our discovery were identified in
COMPASS, most likely due to differences in imputation
reference panels. Genes of interest based on the meta-analysis
results included COL12A1, NTM, PTPRR, and SNTG1, as well as
the LINC01443-LOC64466, LINC02472-PCDH7, and TMTC1-
IPO8 intergenic regions. While we could not replicate our
meta-analysis findings on the single-variant level, rs192315401,
an upstream variant of the LINC02472-PCDH7 reached nominal
significance in COMPASS (Supplementary Table S8, p  3.20E-
04). Results from the meta-analysis of MEGASTROKE top
findings (N  356 variants with p < 1.00E-07) with our AA
data are presented in Supplementary Table S9. The top findings
from MEGASTROKE were not significant in our data and the
race-combined meta-analysis did not notably change any
MEGASTROKE findings. We specifically focused on variants
located within two well-characterized stroke loci: PITX2 (n  118)
and HDAC9 (n  7). For the 118 PITX2 variants, 102 had a
consistent direction of effect across all three cohorts, while the
remaining 16 were consistent across MEGASTROKE and
REGARDS. In the HDAC9 gene locus, all seven variants had
the same direction of effect across all three cohorts
(Supplementary Table S9).
We utilized FUMA to identify any tissue specificity of genes
represented in our top findings. Of 64 unique gene names
identified among variants with p < 1.00E-06, 57 were mapped
to Ensembl identifiers by FUMA. Tissue analysis on an a priori
selected 19 specific tissue types from GTEx revealed statistically
significant, differential upregulation in brain tissues, specifically
the hippocampus (padj  9.67E-05), hypothalamus (padj  2.05E-
03), amygdala (padj  5.28E-03), frontal cortex BA9 (padj  6.36E-
03), putamen basal ganglia (padj  1.56E-02), anterior cingulate
cortex BA24 (padj  1.62E-02), and the caudate basal ganglia (padj 
3.17E-02) (Supplementary Table S10).
Accuracy in predicting incident stroke was assessed in
GenHAT and REGARDS separately, using variant weights for
over 400,000 overlapping variants in the UKB metaPRS
(Abraham et al., 2019) (Supplementary Figure S8). In
GenHAT, model 1 (AUC 62.68%; 95% CI 59.89–65.48%) was
not statistically different than the model adding the metaPRS
(Model 1 + metaPRS; AUC 62.68%; 95% CI 59.89–65.48%; p 
0.981). However, the models adding DM (Model 1 + DM; AUC
64.64%; 95% CI 61.68–67.43%; p  0.025), all the clinical factors
(Model 1 + All Clinical Factors; AUC 66.44%; 95% CI
63.29–69.60%; p  0.003), and all the clinical factors plus the
metaPRS (Model 1 + All Clinical Factors + metaPRS; AUC
66.46%; 95% CI 63.31–69.62; p  0.003) were significantly
different from the reference (i.e., Model one; Supplementary
Table S11). Less than 0.01% of the variance was attributed to the
metaPRS in GenHAT based on the difference of Nagelkerke
pseudo-R2 values between the reference and metaPRS models
(Figure 2; Supplementary Table S11). Similar results were
observed in the REGARDS population. The reference model 1
(AUC 60.88%; 95% CI 57.45–64.30%) was not statistically
different to the metaPRS model (AUC 60.87%; 95% CI
57.45–64.30%; p  0.856). The models adding DM (AUC
62.94%; 95% CI 59.57–66.32%; p  0.035), all the clinical
factors (AUC 64.15%; 95% CI 60.76–67.54; p  0.006), and all
the clinical factors plus the metaPRS (AUC 64.16%; 95% CI
60.77–67.54; p  0.006) were statistically significant, while the
model adding SBP (AUC 62.37%; 95% CI 58.94–65.80%; p 
0.071) was marginally significant. Likewise, less than 0.001% of
the variance was explained by adding the risk score for REGARDS
based on the pseudo-R2 values between the reference and
metaPRS model (Figure 2; SupplementaryTable S12).
DISCUSSION
While numerous stroke outcome GWAS have been published in
the past several years, few studies have been performed
exclusively in AAs. Using data from over 10,700 individuals
from the GenHAT and REGARDS studies, we identified 10
statistically significant and an additional 90 suggestive genetic
variants associated with incident stroke in individuals with HTN.
While none of our findings were directly replicated, their gene
level associations with stroke warrant future replication efforts,
particularly variants located in or near theNTM or PCDH7 genes.
In our meta-analysis, we identified 10 statistically significant
variants, including six intergenic variants between a long-
intergenic non-protein coding RNA (LINC01443) and a
pseudogene (LOC644669). Four of these six variants were
identified in a 2020 intracranial aneurysm (IA) GWAS in an
East Asian population (Bakker et al., 2020). Additional significant
findings include those variants located in COL12A1. This gene
encodes the collagen alpha chain of type XII collagen, which
interacts with type 1 collagen-containing fibrils (UniProt, 2021),
and is a predicted target of the human microRNA-21, which is
induced by Angiotensin II (Wang et al., 2017). Angiotensin II is
the principal effector hormone of the renin-angiotensin system
and increases blood pressure through vasoconstriction and
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increased sodium and water retention (de Leeuw, 1999), which is
clinically relevant to our hypertensive study base.
Of additional interest were the variants downstream of the
TMTC1 (transmembrane O-Mannosyltransferase Targeting
Cadherins 1) gene. TMTC1 encodes a protein that transfers
mannosyl residues to the hydroxyl group of serine or
threonine residues and is primarily dedicated to the cadherin
superfamily (UniProt, 2021). In a prior meta-analysis, variants in
TMTC1 were associated with heart failure (HF) in African
ancestry populations (Smith et al., 2010). Other TMTC1
variants have been associated with lipid metabolism (Talmud
et al., 2009; Della-Morte et al., 2011). A 2011 study using data
from the Northern Manhattan Stroke Study identified an
interaction of TMTC1 with abdominal obesity contributing to
phenotypic variation in left ventricular mass (LVM). Increased
LVM is a known risk factor for HF, stroke, and CVD (Della-
Morte et al., 2011).
The only variants with gene-based replication were located in
the first intron of NTM and upstream of PCDH7. NTM encodes a
member of the IgLON glycosylphosphatidylinositol-anchored
cell adhesion molecular family (Gene, 2004) and is primarily
expressed in the heart and lungs (GTEx Consortium, 2015). A
2012 study found a balanced translocation break in NTM in a
family with intracranial and thoracic aortic aneurysms
(Luukkonen et al., 2012). Furthermore, intronic NTM variants
have been previously implicated in intracerebral hemorrhage and
small vessel ischemic stroke in Europeans (Chung et al., 2019).
Additional studies have reported associations between NTM and
CVD risk factors such as triglyceride levels (Li et al., 2015) and
elevated protein levels in plasma serum (Cao et al., 2015). A
recent study from the International Consortium for
Antihypertensive Pharmacogenomics Studies concluded that
variation in the NTM gene is associated with an increased risk
of adverse cardiovascular outcomes in patients treated with beta-
blockers, as well as an increase in blood pressure after beta-
blocker treatment (McDonough et al., 2021). Although not
statistically significant, we identified 11 variants located
upstream of the PCDH7 (protocadherin 7) gene. In previous
studies, PCDH7 was differentially expressed in aneurysm wall
tissue compared to superficial temporal artery tissue (Shi et al.,
2009), as well as being associated with white matter
hyperintensities in EAs with ischemic stroke (Traylor et al., 2016).
Of the three marginally associated intronic variants within the
SNTG1 (syntrophin gamma-1) gene, rs117962542 has been
previously implicated with stroke risk in a sample of ∼70,000
individuals of European descent from MEGASTROKE (Malik
et al., 2018). SNTG1 encodes a protein that mediates gamma-
enolase trafficking to the plasma membrane and enhances its
neurotrophic activity (UniProt, 2021). An epistasis analysis
performed in 2,800 EAs found an association between an
SNTG1 variant and a history of arterial HTN (Zhou et al.,
2020). Tissue specificity of our top identified genes, specifically
SNTG1 andNTM, showed differential expression in specific brain
tissues, compared to other available tissues from GTEx RNA
sequence data.
Complex diseases, such as stroke, have shown additive genetic
architecture in previous association studies, making PRS a widely
lucrative approach. PRS have been utilized to estimate an
individual’s lifetime genetic risk of disease. While the current
discriminative ability is low in the overall population, PRS may be
useful in populations where there is a higher probability of disease
to assist in prevention or diagnosis, or to inform treatment
choices (Lewis and Vassos, 2020). Currently, there are several
pitfalls of PRS implementation (Arnold and Koenig, 2021). One
of the most impactful is the shortage of data describing PRS
performance in African populations, especially since differences
in allele frequencies and/or LD may limit cross-ethnic utility
(Martin et al., 2019). Our data show that the application of the
genome-wide Abraham metaPRS (derived and validated in
>400K EAs) to >10,000 AAs does not aid in stroke prediction
beyond age, sex, and genetic ancestry (reference model). We
chose to test the AbrahammetaPRS compared to other previously
FIGURE 2 | Stroke prediction model comparison in (A) GenHAT and (B) REGARDS populations. Shown are the area under the receiver operator characteristic
curve (AUC) for eight logistic regressionmodels (with andwithout the Abraham et al. metaPRS and clinical risk factors) used to predict stroke risk in comparison to a basic
model 1 (age + sex +10 ancestry PCs). Error bars represent the 95% confidence intervals of the AUC. Abbreviations: PRS, polygenic risk score; Ref, reference model;
SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; BMI, body mass index, kg/m2; Cig, cigarette smoking at baseline.
Frontiers in Genetics | www.frontiersin.org December 2021 | Volume 12 | Article 7814517
Armstrong et al. Incident Stroke in African Americans
published PRS due to the metaPRS being similarly predictive to
several stroke risk factors, including family history, BP, BMI, and
smoking, as well as reports that the metaPRS (HR 1.26; 95% CI
1.22–1.31 per SD) doubled the predictive accuracy of ischemic
stroke compared to the 90-variant score (HR 1.13, 95% CI
1.10–1.17) (Rutten-Jacobs et al., 2018; Abraham et al., 2019) in
EAs. In both GenHAT and REGARDS, the models accounting for
clinical risk factors (SBP, DBP, DM, BMI, and cigarette smoking)
had the highest predictive accuracy and a negligible improvement
was observed when adding the metaPRS. This suggests that
Abraham score utility is not transferable to AA adults.
Therefore, there remains a strong need for the generation and
validation of stroke scores in minority populations,
specifically AAs.
This study has several strengths. Both GenHAT and
REGARDS collected adjudicated stroke data on a large sample
of AAs with HTN who are disproportionally at-risk for stroke.
We also utilized contemporary genotyping and imputation
methods designed to be more inclusive for research in
minority populations, allowing for more accurate genetic
interrogation of our population (e.g., linkage patterns). We
also must note some weaknesses. We were unable to focus on
stroke type or sub-type due to a lack of that data in ALLHAT/
GenHAT. Additionally, because of our inclusion/exclusion
criteria focused on HTN, our findings may not be
generalizable to younger, healthier populations, or individuals
taking other antihypertensives (i.e., not a thiazide diuretic or ACE
inhibitor). With our study base we may not find HTN genes
related to stroke. However, this is an issue in older AA population
studies of stroke in general as the prevalence of HTN is high (e.g.,
∼70% in the parent REGARDS study). This could also be reflected
in the FUMA results, where there was limited differential
expression in vascular, non-brain tissues (e.g., artery, heart).
Additionally, the GTEx data used in the FUMA analysis is
comprises only 12.9% AA samples. Also, the lack of single-
variant replication in the WPC was limited by the lower allele
frequency variants from the discovery being underrepresented in
the smaller sample size of the WPC. Finally, while the relatively
recent and more racially inclusive TOPMed imputation panel
allowed for interrogation of millions of novel variants, many of
which were of lower allele frequency, it limited our replication
efforts in published data that was imputed into earlier reference
datasets, which highlights the necessity for additional stroke
datasets in AAs.
In conclusion, we identified 10 statistically significant variants
associated with incident stroke in AAs with HTN. The individual
variants were not independently validated in the WPC or
previously reported. However, many gene regions were
biologically plausible and we found gene-based validation in
previously published data. When accounting for case-control
imbalance using SAIGE, our top findings remained significant
and the same direction of the effect size was observed. This
highlights the need for additional validation in large, stroke
studies with AA populations and contemporary methods (e.g.,
use of whole genome sequence data and/or TOPMed imputed
data) to capture genetic variation in non-European populations.
The majority of the results identified genes (NTM, PCDH7,
COL12A1) related to stroke or other CVD related diseases in
Asian and European ancestral populations, with the exception of
one region near TMTC1. This suggests both ancestry-common
and ancestry-specific stroke risk genes are present in AAs. As
hypothesized, this will necessitate discovery efforts to be more
inclusive as genetic diagnostics trained on GWAS data are
considered for use in the clinic. To that point, the published
Abraham composite metaPRS trained in a large sample of EAs
was not validated in the REGARDS or GenHAT study AAs. This
research highlights the need to collect additional data through
large biobanks and consortia efforts that can alleviate the
potential for genetic discovery disparities.
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